SCHEMBL2930924

SCHEMBL2930924

FC(F)(F)c1ccc2c(c1)oc1c3cccc(C(F)(F)F)c3[nH]c21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNMA1 Q12791 1/20 0.49
KIF11 P52732 5/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
KDM4E B2RXH2 2/20 0.43
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
POLB P06746 1/20 0.43
HPGD P15428 1/20 0.43
HTT P42858 1/20 0.43
KMT2A Q03164 1/20 0.43
PIM1 P11309 3/20 0.40
PIM3 Q86V86 3/20 0.40
HSD17B10 Q99714 1/20 0.35
EPHX2 P34913 2/20 0.35
F7 P08709 1/20 0.34
F3 P13726 1/20 0.34
CDK4 P11802 1/20 0.34
CCND1 P24385 1/20 0.34
CDC14B O60729 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2932784 0.85 KCNMA1 (0.57) KCNMA1KIF11SMN1; SMN2ALDH1A1PIM1
SCHEMBL2930598 0.82 KCNMA1 (0.46) KCNMA1KIF11SMN1; SMN2KDM4EMEN1
SCHEMBL2932491 0.82 KCNMA1 (0.50) KCNMA1KIF11PIM1PIM3F7
SCHEMBL2933540 0.81 KCNMA1 (0.67) KCNMA1KDM4EMEN1ALDH1A1HPGD
SCHEMBL2925140 0.78 KCNMA1 (0.61) KCNMA1KIF11MEN1LMNAKMT2A
SCHEMBL2931043 0.78 KCNMA1 (0.52) KCNMA1KIF11KDM4EMEN1ALDH1A1
SCHEMBL2931271 0.77 KCNMA1 (0.50) KCNMA1KIF11KDM4EMEN1KMT2A
SCHEMBL2934874 0.76 KCNMA1 (0.50) KCNMA1KIF11PIM1PIM3F7
SCHEMBL2932286 0.74 KCNMA1 (0.47) KCNMA1KIF11PIM1PIM3CDK4
SCHEMBL31083618 0.72 KIF11 (0.74) KIF11SMN1; SMN2KDM4EMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7812177-B2 Potassium channel opener having benzofuroindole skeleton ANYGEN CO., LTD. (KR) 2010-10-12 US disclosed
EP-1861092-B1 POTASSIUM CHANNEL OPENER HAVING BENZOFUROINDOLE SKELETON ANYGEN CO LTD (KR) 2010-09-15 EP disclosed
EP-1861092-A4 POTASSIUM CHANNEL OPENER HAVING BENZOFUROINDOLE SKELETON ANYGEN CO LTD (KR) 2009-04-15 EP disclosed
US-20080194837-A1 Potassium Channel Opener Having Benzofuroindole Skeleton ANYGEN CO., LTD. (KR) 2008-08-14 US disclosed
EP-1861092-A1 POTASSIUM CHANNEL OPENER HAVING BENZOFUROINDOLE SKELETON Anygen Co., Ltd. (KR) 2007-12-05 EP disclosed
WO-2006096030-A1 POTASSIUM CHANNEL OPENER HAVING BENZOFUROINDOLE SKELETON ANYGEN CO., LTD. (KR) 2006-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194837-A1 Potassium Channel Opener Having Benzofuroindole Skeleton KCNJ2, KCNN3, KCNH2 KCNMA1 41/4885KIF11 636/4885SMN1; SMN2 3662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.